Reported results
- CyPath Lung test unit sales increased 100% through Q3 compared to the first nine months of 2025.
- CyPath Lung testing revenue for the first nine months of 2026 increased 79% to approximately $1.1 million.
- The number of ordering physicians increased by 89% in the third quarter of 2026 compared to the third quarter of 2025.
- Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million.
- Operating expenses for the third quarter of 2026 were approximately $4.6 million.
- Net loss for the quarter ended September 30, 2026, was approximately $5.3 million.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.
